Navigation Links
ISTA Pharmaceuticals' New Drug Application for Bepreve(TM) Accepted for Review by U.S. Food and Drug Administration
Date:1/15/2009

IRVINE, Calif., Jan. 15 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today announced that ISTA's New Drug Application (NDA) for Bepreve(TM) (bepotastine ophthalmic solution) has been accepted for review by the U.S. Food and Drug Administration (FDA). The Company is seeking approval for Bepreve as an eye drop treatment for ocular itching associated with allergic conjunctivitis. The Company expects a standard review of ten months and has been given a user fee action date of September 12, 2009.

ISTA's Phase III clinical studies with Bepreve demonstrated highly statistically significant reductions in the primary endpoints of ocular itching. In addition, the results showed Bepreve had a statistically significant effect on the rapidity of response and on additional signs or symptoms of ocular allergy, including improvement in nasal symptoms. There were no serious ocular adverse events reported in patients dosed with Bepreve.

About Bepreve(TM) (bepotastine ophthalmic solution)

Assuming approval from the FDA, Bepreve would participate in ISTA's largest market to date. IMS Health estimates the U.S. ocular allergy market generated approximately $560 million in sales in 2007. Bepreve is a non-sedating, highly selective antagonist of the histamine (H1) receptor. It has a stabilizing effect on mast cells and it suppresses the migration of eosinophils into inflamed tissues. The compound's primary mechanisms of action are believed to make it an effective treatment against the signs and symptoms of allergic conjunctivitis.

Bepotastine was approved in Japan for use as a systemic drug in the treatment of allergic rhinitis and urticaria/pruritus in July 2000 and January 2002, respectively, and is marketed by Mitsubishi Tanabe Pharma Corporation (formerly Tanabe Seiyaku Co., Ltd.) under the b
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... BOULDER, Colo. , April 27, 2015 ... will report financial results for the third ... conference call to discuss those results on ... Executive Officer will lead the call.Date:Monday, May ... Code: 5249676 Webcast, including Replay and Conference ...
(Date:4/27/2015)... Inc. (NYSE: CRY ), a leading medical device ... surgery, announced today that it has received a close-out ... ("FDA") verifying that the Company has successfully implemented corrective ... received from the FDA in January 2013. ... by the FDA at CryoLife,s manufacturing facility and headquarters ...
(Date:4/27/2015)... NEW YORK , April 27, 2015   ... management solutions, will showcase advances in monitored care that ... the upcoming ATA 2015 Conference, May 2-5 ... Center. AMC Health will share information about ... monitored care to help transform and personalize healthcare delivery ...
Breaking Medicine Technology:CryoLife Announces Resolution of FDA Warning Letter 2AMC Health to Showcase Advances in Monitored Care at ATA 2015 2AMC Health to Showcase Advances in Monitored Care at ATA 2015 3AMC Health to Showcase Advances in Monitored Care at ATA 2015 4
... DIEGO, Oct. 13 RESMED INC. (NYSE: RMD ... will release its results for the first quarter of fiscal ... ResMed,s results will be issued after 1:00 p.m. Pacific Time ... to review its results, market trends, and future outlook. ...
... Care Continuum Alliance honored Kaiser Permanente,s ALL/PHASE initiative ... on Health" at The Forum 10 conference ... low-cost and generic medications and clinical interventions to reduce ... communities, including those served by safety net organizations. ...
Cached Medicine Technology:ResMed Announces Conference Call and Webcast to Discuss First Quarter 2011 Results 2Kaiser Permanente's ALL/PHASE Initiative Wins 2010 Care Continuum Alliance Quality Impact Award for Greatest Impact on Health 2Kaiser Permanente's ALL/PHASE Initiative Wins 2010 Care Continuum Alliance Quality Impact Award for Greatest Impact on Health 3
(Date:4/27/2015)... A new type of festival is emerging ... on Tap at the Science Museum of Virginia not only ... science hops for a bold, new flavor. , The 21+ ... up the science behind these frothy beverages. Guests uncover the ... at the ingredients that go into beer with Original Gravity ...
(Date:4/27/2015)... Calif. (PRWEB) April 27, 2015 ... surrounding the molecular basis of an inherited disorder ... but now also arises in other populations of ... Through a series of elegant experiments, the researchers ... type of leukodystrophy that is an incurable and ...
(Date:4/27/2015)... (PRWEB) April 27, 2015 Diamond reflective ... unneeded risk of damaging hot spots. , Gorilla Grow ... because of their sturdy structure and strong material that ... was design to effectively distribute lumens and eliminates hot ... most benefit from grow lights and produces the highest ...
(Date:4/27/2015)... (PRWEB) April 27, 2015 Thanks to ... Health, researchers from a half-dozen institutions, including American University, ... epidemiological, basic and social and behavioral research aimed at ... D.C. residents are living with HIV or AIDS, according ... 2.4 percent of D.C.'s population over the age of ...
(Date:4/27/2015)... TX (PRWEB) April 27, 2015 Guided ... the field of patient experience and its collaboration with ... research, The Beryl Institute identifies eight essential actions ... , The Beryl Institute believes organizations and systems committed ... Identify and support accountable leadership with committed ...
Breaking Medicine News(10 mins):Health News:Science on Tap at the Science Museum of Virginia 2Health News:UC Davis Makes Breakthrough in Understanding Canavan Disease 2Health News:UC Davis Makes Breakthrough in Understanding Canavan Disease 3Health News:UC Davis Makes Breakthrough in Understanding Canavan Disease 4Health News:D.C. Center for AIDS Research Established with New Grant from NIH 2Health News:D.C. Center for AIDS Research Established with New Grant from NIH 3Health News:Guiding Principles for Patient Experience Excellence Identified by The Beryl Institute 2
... Maureen Salamon HealthDay Reporter , MONDAY, May ... heart attack are at increased risk of suffering another ... certain types of prescription and over-the-counter painkillers, including ... Danish researchers analyzed nationwide records of almost 84,000 ...
... MAA study by scientists at Schepens Eye Research Institute shows ... of glasses used to magnify traffic signs and lights may ... second eye. The study results, which will be published ... the first evidence that--under more realistic viewing conditions than in ...
... Reporter , MONDAY, May 9 (HealthDay News) -- A simple ... with a chronic bowel disease, a new study has found. ... at Chapel Hill, found that women with irritable bowel syndrome ... reduction in symptoms, far surpassing a nearly 12 percent reduction ...
... new, promising marker for diagnosing prostate cancer has been ... unique method developed at the Department of Immunology, Genetics ... the journal Proceedings of the National Academy of ... and fewer unnecessary operations. The PSA marker used ...
... gas appears to directly impact the source of the ... Health Sciences University researchers report. The short-acting gas ... chains that ultimately deform red blood cells and prompting ... said Dr. C. Alvin Head, Chairman of GHSU,s Department ...
... 2011 (BRONX, NY) An estimated five million ... of cases to rise dramatically as the population ages ... College of Medicine of Yeshiva University are among those ... Einstein Aging Study (EAS) , which examines both ...
Cached Medicine News:Health News:After Heart Attack, Certain Painkillers May Raise Risk for Recurrence 2Health News:After Heart Attack, Certain Painkillers May Raise Risk for Recurrence 3Health News:Single bioptic telescope for low vision driving may not obscure road view of second eye 2Health News:Single bioptic telescope for low vision driving may not obscure road view of second eye 3Health News:Mindful Meditation Might Ease Irritable Bowel Syndrome 2Health News:Mindful Meditation Might Ease Irritable Bowel Syndrome 3Health News:New marker offers hope for more reliable detection of prostate cancer 2Health News:Nitric oxide impacts source of sickle cell pain crisis 2Health News:Einstein secures $11 million to continue research on brain aging and Alzheimer's disease 2
The ring maintains the bag tension avoiding the development of posterior capsule pleats. It is also established to compensate the efforts induced during the bag retraction....
... Type 14, 14A and 14C have been approved. ... to accommodate the variations in the size of ... tension rings are designed to stabilize the capsule ... large panel of U.S. ophthalmologists. For implatations ...
... is a device designed for permanent implantation ... removal surgery. It provides secondary capsular bag ... The CTR is a uniplanar, 270-degree, semi-circle ... absorbing polymethylmethacrylate (PMMA) with one manipulation eyelet ...
Stainless steel cartilage scissors....
Medicine Products: